Cohance Life

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE03QK01018
  • NSEID: COHANCE
  • BSEID: 543064
INR
426.80
3.5 (0.83%)
BSENSE

Jun 12, 03:30 PM

BSE+NSE Vol: 3.83 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Rubicon Research
Granules India
Caplin Point Lab
Alivus Life
Concord Biotech
Natco Pharma
OneSource Speci.
ERIS Lifescience
Jubilant Pharmo
Alembic Pharma
Cohance Life

Why is Cohance Lifesciences Ltd ?

1
Poor long term growth as Operating profit has grown by an annual rate -10.18% of over the last 5 years
2
With a fall in Net Sales of -0.54%, the company declared Very Negative results in Mar 26
  • The company has declared negative results for the last 3 consecutive quarters
  • PAT(Latest six months) At Rs 66.63 cr has Grown at -76.62%
  • PBT LESS OI(Q) At Rs 38.26 cr has Fallen at -53.4% (vs previous 4Q average)
  • NET SALES(Latest six months) At Rs 1,163.67 cr has Grown at -23.27%
3
With ROE of 5, it has a Very Expensive valuation with a 4.2 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -58.35%, its profits have fallen by -60.8%
4
100% of Promoter Shares are Pledged
  • In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
5
Underperformed the market in the last 1 year
  • Even though the market (BSE500) generated negative returns of -2.24% in the last 1 year, its fall in the stock was much higher with a return of -58.35%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Cohance Life for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Cohance Life
-58.35%
-1.16
50.18%
Sensex
-7.55%
-0.58
13.06%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
17.57%
EBIT Growth (5y)
-10.18%
EBIT to Interest (avg)
45.93
Debt to EBITDA (avg)
0.32
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.69
Tax Ratio
27.49%
Dividend Payout Ratio
0
Pledged Shares
100.00%
Institutional Holding
27.39%
ROCE (avg)
30.19%
ROE (avg)
17.35%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
83
Industry P/E
34
Price to Book Value
4.17
EV to EBIT
68.44
EV to EBITDA
38.41
EV to Capital Employed
4.12
EV to Sales
7.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.01%
ROE (Latest)
5.00%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
NO KEY POSITIVE TRIGGERS
-21What is not working for the Company
PAT(Latest six months)

At Rs 66.63 cr has Grown at -76.62%

PBT LESS OI(Q)

At Rs 38.26 cr has Fallen at -53.4% (vs previous 4Q average

NET SALES(Latest six months)

At Rs 1,163.67 cr has Grown at -23.27%

ROCE(HY)

Lowest at 6.35%

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.33 times

EPS(Q)

Lowest at Rs 0.51

Loading Valuation Snapshot...

Here's what is not working for Cohance Life

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 38.26 cr has Fallen at -53.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 82.19 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 26.44 cr has Fallen at -64.9% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 75.27 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Latest six months
At Rs 1,163.67 cr has Grown at -23.27%
Year on Year (YoY)
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 38.26 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Lowest at Rs 0.51
in the last five quarters
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Debtors Turnover Ratio- Half Yearly
Lowest at 3.33 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio